Back to Search
Start Over
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
- Source :
- Molecules and Cells
- Publication Year :
- 2021
- Publisher :
- Korean Society for Molecular and Cellular Biology, 2021.
-
Abstract
- Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti–PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC.
- Subjects :
- programmed death ligand-1
Lung Neoplasms
medicine.drug_class
medicine.medical_treatment
Monoclonal antibody
immune checkpoint inhibitors
03 medical and health sciences
0302 clinical medicine
Acquired resistance
Carcinoma, Non-Small-Cell Lung
medicine
Humans
Lung cancer
Molecular Biology
non-small cell lung cancer
programmed death-1
030304 developmental biology
0303 health sciences
business.industry
acquired resistance
Antibodies, Monoclonal
Cell Biology
General Medicine
Immunotherapy
medicine.disease
Ligand (biochemistry)
Clinical trial
Drug Resistance, Neoplasm
Cancer research
Minireview
Non small cell
business
030217 neurology & neurosurgery
Programmed death
Subjects
Details
- ISSN :
- 02191032
- Volume :
- 44
- Database :
- OpenAIRE
- Journal :
- Molecules and Cells
- Accession number :
- edsair.doi.dedup.....9dc13ca363047295c4e04e59c22abeb3